Quercetin and Its Lecithin-Based Formulation: Potential Applications for Allergic Diseases Based on a Narrative Review.

Summary

This narrative review, published in Nutrients (2025), synthesises existing evidence on quercetin — a naturally occurring flavonoid — and its known limitations regarding oral bioavailability, alongside the proposed advantages of a lecithin-based delivery system intended to address this limitation. The authors explore the mechanistic basis for quercetin's relevance in allergic disease, including its capacity to modulate inflammatory mediators and inhibit histamine release. The review suggests that lecithin-based formulations may enhance quercetin's therapeutic potential in allergic conditions, though the authors likely acknowledge that robust clinical trial evidence remains limited.

UK applicability

The findings are broadly applicable to UK clinical and public health contexts, particularly given the high prevalence of allergic rhinitis and atopic conditions in the UK population; however, as a narrative review of largely preclinical and early-phase evidence, direct translation to UK clinical guidelines would require corroboration from well-designed randomised controlled trials.

Key measures

Bioavailability parameters; anti-inflammatory and antihistaminic activity; mast cell stabilisation; symptom outcomes in allergic conditions (e.g. allergic rhinitis, asthma, atopic dermatitis)

Outcomes reported

The review examined the pharmacological properties of quercetin, including its anti-inflammatory, antihistaminic, and mast-cell-stabilising effects, and assessed the potential clinical utility of a lecithin-based formulation designed to improve quercetin's bioavailability in the context of allergic diseases.

Topic tags